Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
Verified American Company Independently reviewed and approved · June 2026

Guardant Health, Inc. (GH)

$147.33 -1.91% NASDAQ: GH · 15-min delayed
  • PALO ALTO, California
  • Public · NASDAQ: GH
  • 2,506 employees
$16.7BMarket cap
$982.0MRevenue · FY2025
-$416.3MNet income
2,506Employees
GHNASDAQ
2018IPO

About Guardant Health, Inc.

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

American Credentials

Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →

Reported figures

Financial summary

Revenue FY2025
$982.0M
Net income
-$416.3M
Total assets
$2.0B
Market cap
$16.7B
Gross margin
64.5%
Operating margin
-44.5%
Net margin
-42.4%

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2025

Financial statements

Income statement

Revenue
$982.0M
Cost of revenue
$349.0M
Gross profit
$633.0M
Operating expenses
$1.1B
Operating income
-$437.2M
Income tax
-$1.3M
Net income
-$416.3M
EPS (basic)
$-3.32
EPS (diluted)
$-3.32

Balance sheet

Total assets
$2.0B
Current assets
$1.5B
Total liabilities
$2.1B
Current liabilities
$302.7M
Shareholders’ equity
-$99.3M

Cash flow

Operating cash flow
-$184.8M
Investing cash flow
-$627.2M
Financing cash flow
$671.1M
Net cash flow
-$140.8M

Statements via Polygon.io (SEC filings)

NASDAQ: GH
$147.33 -1.91%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$40.98 $170.77

52-week range

Market cap
$16.7B
EPS (diluted)
$-3.32
Shares outstanding
113.1M
Open
Day range
Prev close
Volume
IPO date
Oct 4, 2018

Guardant Health, Inc. (GH) Stock Price

  • Reported a net loss of $416.3M in FY2025.
  • Revenue grew 163% from FY2021 to FY2025.
  • Gross margin of 64.5%, net margin -42.4%.
  • Trading 14% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Guardant Health, Inc..

Write a review
Newsroom

News about Guardant Health, Inc.

News & sentiment via Polygon.io

FAQ

Guardant Health, Inc.: frequently asked questions

Is Guardant Health, Inc. an American company?

Yes — Guardant Health, Inc. is an American company headquartered in Palo Alto, California. Its American-origin credentials have been independently reviewed and verified by americancompanies.com.

Where is Guardant Health, Inc. headquartered?

Guardant Health, Inc. is headquartered in Palo Alto, California, United States.

Is Guardant Health, Inc. publicly traded?

Yes — Guardant Health, Inc. is a publicly traded company. Its stock trades under the ticker symbol GH on the NASDAQ.

What does Guardant Health, Inc. do?

Guardant Health, Inc. is an American Medical Devices company in the Health & Beauty sector.

Explore

Similar companies

Browse all →